Corcept Therapeutics Beats Q2 Estimates, Cuts Guidance and Advances NDA for New Cancer Drug

Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the 12 Stocks with Consistent Growth to Invest In.

Following a strong positive second quarter, the company lowers its full-year guidance and announces the NDA acceptance for a new drug by the FDA.

Corcept Therapeutics Incorporated (NASDAQ:CORT) reported its Q2 2025 earnings on July 31, 2025, in which it highlighted a 45% EPS beat, achieving $0.29 per share against an estimated $0.20. The company’s revenue reached $194.4 million, an 18.7% increase year-over-year. Despite the positive numbers, however, the company reduced its full-year revenue guidance to $850-$900 million.

Additionally, the company announced that the FDA had formally filed a New Drug Application (NDA) for its drug candidate, Relacorilant, as a treatment for platinum-resistant ovarian cancer. The FDA has set a decision date for July 11, 2026. With the filing, the company de-risks a major portion of its pipeline. The company has further stated that it will present new data from the pivotal Phase 3 ROSELLA trial at the European Society for Medical Oncology (ESMO) annual meeting on October 19, 2025.

The 10-year performance of 1534.68%, Corcept Therapeutics Incorporated (NASDAQ:CORT), gains a positive interpretation reflecting a strong foothold in the market.

Corcept Therapeutics Incorporated (NASDAQ:CORT), founded in 1998, is a commercial-stage pharmaceutical company. The California-based company develops drugs, like Korlym, for severe metabolic, psychiatric, and oncologic disorders by modulating the effects of the hormone cortisol.

While we acknowledge the potential of CORT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 High-Risk High-Reward Growth Stocks to Buy Right Now and 13 Best Fortune 500 Dividend Stocks to Invest In

Disclosure. None.